BioTuesdays

Category - Markets

Kazia

Maxim starts Kazia Therapeutics at buy; PT $18

Maxim Group initiated coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and $18 price target. The stock closed at $10.71 on Oct. 13. Kazia is developing two oncology drug candidates: paxalisib, for brain...

HCW starts Progenity at buy; PT $4

H.C. Wainwright launched coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $4. The stock closed at $2.04 on Oct. 13. Progenity’s differentiated R&D pipeline primarily focuses on employing...

Ladenburg starts Renovacor at buy; PT $22

Ladenburg Thalmann initiated coverage of Renovacor (NASDAQ:RCOR) with a “buy” rating and $22 price target. The stock closed at $7.93 on Oct. 13. Renovacor is a preclinical-stage biotech company focused on developing...

Ardelyx-2021

Ladenburg cuts Ardelyx to neutral from buy

Ladenburg Thalmann downgraded Ardelyx (NASDAQ:ARDX) to “neutral” from “buy” and removed its price target, citing an unproductive post-complete response letter (CRL) Type A meeting with the FDA. The stock closed at $1.09...

Neuronetics Logo

BTIG cuts Neuronetics to neutral

BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...

Dice-Therapeutics

SVB Leerink starts DICE Therapeutics at OP; PT $46

SVB Leerink launched coverage of Dice Therapeutics (NASDAQ:DICE) with an “outperform” rating and $46 price target. The stock closed at $26.49 on Oct. 8. DICE is a biopharmaceutical company leveraging its proprietary...

HCW starts Vyant Bio at buy; PT $5

H.C. Wainwright initiated coverage of Vyant Bio (NASDAQ:VYNT) with a “buy” rating and price target of $5. The stock closed at $2.21 on Oct. 5. Vyant is a biotechnology company focused on identifying therapeutic drugs...

RenovoRX

Maxim starts RenovoRx at buy; PT $15

Maxim Group launched coverage of RenovoRx (NASDAQ:RNXT) with a “buy” rating and price target of $15. The stock closed at $5.72 on Oct.5. RenovoRx is developing a therapeutic platform known as, RenovoTAMP (Trans-Arterial...